Last reviewed · How we verify
sugammadex ED90
Sugammadex is a selective relaxant binding agent that encapsulates and inactivates rocuronium and vecuronium neuromuscular blocking agents, rapidly reversing neuromuscular blockade.
Sugammadex is a selective relaxant binding agent that encapsulates and inactivates rocuronium and vecuronium neuromuscular blocking agents, rapidly reversing neuromuscular blockade. Used for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery.
At a glance
| Generic name | sugammadex ED90 |
|---|---|
| Also known as | ED90 |
| Sponsor | Faculdade de Ciências Médicas da Santa Casa de São Paulo |
| Drug class | Selective relaxant binding agent |
| Target | Rocuronium and vecuronium (steroidal neuromuscular blocking agents) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Sugammadex works by forming a tight 1:1 complex with steroidal neuromuscular blocking agents (rocuronium and vecuronium), removing them from the neuromuscular junction and preventing their interaction with nicotinic acetylcholine receptors. This mechanism allows rapid reversal of neuromuscular blockade without the need for acetylcholinesterase inhibitors. The ED90 designation refers to the dose required to reverse 90% of neuromuscular blockade.
Approved indications
- Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery
Common side effects
- Bradycardia
- Hypotension
- Nausea
- Vomiting
- Recurarization
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |